Stemson Therapeutics hair follicle neogenesis
Development of Stemson Therapeutics hair follicle neogenesis for androgenetic alopecia was discontinued by Stemson Therapeutics.
Grew new human follicles from induced pluripotent stem cells in mice, and ran out of money before reaching a clinical trial.
This programme is no longer being actively pursued.
- Developed by
- Stemson Therapeutics
- Current phase
- Discontinued
- Mechanism
- Stem cell activation
- Indications
- Androgenetic alopecia
- Also known as
- Stemson
- Last public activity
- No trials on record
- Copy last reviewed
- September 2026
- Record confidence
- Medium
Development stopped.
Uses stem or progenitor cells to regenerate or replace follicle tissue.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
This category, building new follicles rather than rescuing existing ones, is the only route that could restore hair to a fully bald scalp. It is also the furthest from the clinic, and Stemson is why this register keeps failures: it ceased operations in late 2024 without ever reaching a first-in-human trial, for want of funding by its chief executive's own account rather than because of any scientific result. Note the sourcing: the company was private, so there is no filing to point at and this rests on trade press, which is why the row is not marked HIGH. Apply the same scepticism to every timeline you read for the rest of this category.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Stemson Therapeutics Shuts Down — Press
- Stemson Therapeutics announces technological breakthrough in new hair growth (iPSC-derived follicles in humanised mice) — Company release, February 2024
Related programmes
Other programmes in the register with the same mechanism: Stem cell activation.
Cite this page
Hair Pipeline, "Stemson Therapeutics hair follicle neogenesis — development record", hairpipeline.com/pipeline/stemson